CCN4 and pulmonary fibrosis: Interestingly, the orotracheal application of WISP-1 neutralizing antibodies to the lung has been shown to decrease bleomycin-induced lung fibrosis [21], suggesting that WISP-1 might be a new target for anti-fibrotic therapy [22].